APGE · Apogee Therapeutics, Inc.

This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date.

Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.

This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date.

Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.50 to $132.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.455 to $82.440, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.470 to $83.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.00 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.00 to $82.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.15 to $85.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.17 to $85.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.